实用医学杂志 ›› 2022, Vol. 38 ›› Issue (8): 991-996.doi: 10.3969/j.issn.1006⁃5725.2022.08.015

• 临床研究 • 上一篇    下一篇

急性髓系白血病患者外周血CD8+ T淋巴细胞中 MagT1水平监测的临床价值

王晶1 向健2 胡淑芳3 朱艳坤1 钟玉钗4   

  1. 武汉市汉口医院1 检验科,3 内分泌科(武汉 430012);2 天门市第一人民医院输血科(湖北天门 431700); 4 南方医科大学附属东莞医院检验科(广东东莞 523039)

  • 出版日期:2022-04-25 发布日期:2022-04-25
  • 通讯作者: 钟玉钗 E⁃mail:Yuchai2147@163.com
  • 基金资助:
    湖北省卫生计生委科研项目(编号:WJ2019H549)

Clinical value of MagT1 level in peripheral blood T lymphocytes in patients with acute myeloid leukemia

WANG Jing*,XIANG Jian,HU Shufang,ZHU Yankun,ZHONG Yuchai.   

  1. Department of Laboratory Medicine Wuhan Hankou Hospital,Wuhan 430012,China

  • Online:2022-04-25 Published:2022-04-25
  • Contact: ZHONG Yuchai E⁃mail:Yuchai2147@163.com

摘要:

目的 探讨急性髓系白血病(acute myeloid leukemia,AML)患者外周血 CD8+ T 淋巴细胞中 Mg2+ 转运蛋白 1(MagT1)水平监测的临床价值。方法 收集 2014 3 月至 2018 12 月收治的新发 AML 197 例,同期体检者 60 例。分离外周血单个核细胞(PBMCs)和 CD8+ T 细胞备用。全自动生化分析仪检 测血清 Mg2+ 浓度,RT⁃qPCR 检测 PBMCs MagT1 mRNA 表达。根据 NCCN AML 指南将 AML 患者分为低、 中、高风险组,RT⁃qPCR Western blot 检测患者 CD8+ T 细胞中 MagT1 mRNA 和蛋白表达水平;流式细胞术 检测细胞 PD⁃1 Tim⁃3 表达水平;Spearson 相关性分析 MagT1 蛋白与 PD⁃1 Tim⁃3 表达的相关性;Kaplan⁃ Meier 曲线分析 CD8+ T 细胞 MagT1 蛋白表达与患者无事件生存期(EFS)和总生存期(OS)的关系;采用受试 者工作特征(ROC)曲线评估 MagT1 蛋白表达水平对 AML 患者风险分层及预后的预测价值。结果 与对 照组比较,AML 患者外周血中 Mg2+ 浓度降低,PBMCs MagT1 mRNA 相对表达量下调。与低风险组比较, 中、高风险组患者 CD8+ T 细胞中 MagT1 mRNA 和蛋白相对表达量降低,而 PD⁃1 Tim⁃3 表达水平升高。 CD8+ T 细胞中 MagT1 蛋白与 PD⁃1 Tim⁃3 表达水平呈负相关;MagT1 蛋白高表达患者的 EFS OS 高于 MagT1 蛋白低表达患者;MagT1 表达水平对 AML 患者预后(AUC = 0.866,95%CI:0.817 ~ 0.915)及风险分层 AUC = 0.724,95%CI:0.642 ~ 0.806)均具有一定的评估价值。结论 AML 患者外周血 CD8 + T 细胞中 MagT1 的表达降低与患者不良风险分层、CD8+ T 淋巴细胞耗竭和不利的生存状况相关,对评估 AML 患者 风险及预测预后有重要价值。

关键词:

急性髓系白血病, CD8+ T淋巴细胞, Mg2+ 转运蛋白1, 预后

Abstract:

Objective To explore the clinical value of Mg2+ transporter 1(MagT1)expression in peripheral blood CD8 + T lymphocytes in patients with acute myeloid leukemia(AML). Methods One hundred and nighty⁃ seven new⁃onset AML patients admitted to our hospital from March 2014 to December 2018 and 60 physical exam⁃ iners in the same period were enrolled in the study. Peripheral blood monocytes cells(PBMCs)and CD8 + T cells were isolated. The concentration of serum Mg2+ was detected by automatic biochemical analyzer,and the expression of MagT1 mRNA in PBMCs was detected by RT⁃qPCR. AML patients were divided into low,medium and high risk groups according to NCCN AML guidelines. The expression of MagT1 mRNA and protein in CD8+ T cells were detected by RT⁃qPCR and Western blot. The expression of PD⁃1 and Tim⁃3 was detected by flow cytometry. The correlation between MagT1 protein and the expression of PD⁃1 and Tim⁃3 was analyzed by Spearson correlation assay. The relationship between MagT1 protein expression in CD8+ T cells and event free survival(EFS)and overall survival(OS)were analyzed by Kaplan ⁃Meier curve. Receiver operating characteristic(ROC)curve was used to evaluate the predictive value of MagT1 protein expression level in risk stratification and prognosis of AML patients. Results Compared with the control group,the Mg2+ concentration in peripheral blood of AML patients decreased and the relative expression of MagT1 mRNA in PBMCs decreased. Compared with the low⁃risk group,the relative expression of MagT1 mRNA and protein in CD8+ T cells in the medium and high⁃risk groups decreased,while the levels of PD⁃1 and Tim⁃3 increased. The expression of MagT1 protein in CD8+ T cells was negatively correlated with the expression levels of PD⁃1 and Tim⁃3. The EFS and OS of patients with high expression of MagT1 protein were higher than those with low expression of MagT1 protein. The expression level of MagT1 has evaluation value for prognosis(AUC = 0.866,95%CI:0.817 ~ 0.915)and risk stratification(AUC = 0.724,95%CI:0.642 ~ 0.806 of AML patients. Conclusion The decreased expression of MagT1 in peripheral blood CD8+ T cells in patients with AML is associated with adverse risk stratification,CD8 + T lymphocyte depletion and adverse survival. It has important value in evaluating the risk and predicting the prognosis of patients with AML.

Key words:

acute myeloid leukemia, CD8+ T lymphocytes, magnesium transporter 1, prognosis